1. Home
  2. RNAZ vs FTEL Comparison

RNAZ vs FTEL Comparison

Compare RNAZ & FTEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNAZ
  • FTEL
  • Stock Information
  • Founded
  • RNAZ 2016
  • FTEL 2007
  • Country
  • RNAZ United States
  • FTEL Australia
  • Employees
  • RNAZ N/A
  • FTEL N/A
  • Industry
  • RNAZ Biotechnology: Pharmaceutical Preparations
  • FTEL
  • Sector
  • RNAZ Health Care
  • FTEL
  • Exchange
  • RNAZ Nasdaq
  • FTEL Nasdaq
  • Market Cap
  • RNAZ 8.7M
  • FTEL 9.1M
  • IPO Year
  • RNAZ 2021
  • FTEL 2023
  • Fundamental
  • Price
  • RNAZ $14.80
  • FTEL $5.89
  • Analyst Decision
  • RNAZ Strong Buy
  • FTEL
  • Analyst Count
  • RNAZ 1
  • FTEL 0
  • Target Price
  • RNAZ $280.00
  • FTEL N/A
  • AVG Volume (30 Days)
  • RNAZ 387.0K
  • FTEL 379.7K
  • Earning Date
  • RNAZ 11-13-2025
  • FTEL 11-27-2025
  • Dividend Yield
  • RNAZ N/A
  • FTEL N/A
  • EPS Growth
  • RNAZ N/A
  • FTEL N/A
  • EPS
  • RNAZ N/A
  • FTEL N/A
  • Revenue
  • RNAZ N/A
  • FTEL $4,990,695.00
  • Revenue This Year
  • RNAZ N/A
  • FTEL N/A
  • Revenue Next Year
  • RNAZ N/A
  • FTEL N/A
  • P/E Ratio
  • RNAZ N/A
  • FTEL N/A
  • Revenue Growth
  • RNAZ N/A
  • FTEL 29.02
  • 52 Week Low
  • RNAZ $6.15
  • FTEL $4.61
  • 52 Week High
  • RNAZ $739.20
  • FTEL $792.00
  • Technical
  • Relative Strength Index (RSI)
  • RNAZ 84.37
  • FTEL 63.58
  • Support Level
  • RNAZ $10.32
  • FTEL $4.61
  • Resistance Level
  • RNAZ $12.28
  • FTEL $6.09
  • Average True Range (ATR)
  • RNAZ 0.87
  • FTEL 1.18
  • MACD
  • RNAZ 0.57
  • FTEL -0.08
  • Stochastic Oscillator
  • RNAZ 91.34
  • FTEL 32.70

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

About FTEL Fitell Corporation

Fitell Corp engages in primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiaries. It operates in two segments: online fitness equipment distribution and licensing business to service the large and growing boutique fitness sector of the broader health and fitness club industry. The majority fitness equipment business is conducted in Australia via its own e-commerce platform and, through third-party sites. Licensing service offers a turnkey solution for personal training studios and commercial gym chains. The company earns maximum of revenue for retail.

Share on Social Networks: